Skip to main content

Advertisement

SpringerLink
Log in

Pharmacologic treatment of neuropathic pain

  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Neuropathic pain, or pain after nervous system injury, can be very refractory to pharmacologic interventions. Through a better understanding of the pathophysiology of neuropathic pain, it has been suggested that nonopioid agents, such as antidepressants and anticonvulsants, may be more efficacious in the treatment of neuropathic pain than common analgesics, such as opioids or nonsteroidal anti-inflammatory drugs. However, this has not been consistently demonstrated in clinical studies. Conversely, many confounding factors of neuropathic pain make it difficult to interpret clinical studies. Therefore, we must develop a better understanding of the preclinical models of neuropathic pain to better understand the application of new and old drugs to the human neuropathic pain state. This article provides an overview of the commonly used preclinical neuropathic pain models, followed by a summary of the efficacy of currently available agents in preclinical pain models and human correlates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kim SH, Chung JM: An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992, 50:355–363.

    Article  PubMed  CAS  Google Scholar 

  2. Sheen K, Chung JM: Signs of neuropathic pain depend on signals from injured nerve fibers in a rat model. Brain Res 1993, 610:62–68.

    Article  PubMed  CAS  Google Scholar 

  3. Kim SH, Na HS, Sheen K, et al.: Effects of sympathectomy on a rat model of peripheral neuropathy. Pain 1993, 55:85–92.

    Article  PubMed  CAS  Google Scholar 

  4. Bennett GJ, Xie YK: A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33:87–107.

    Article  PubMed  CAS  Google Scholar 

  5. Perrot S, Attal N, Ardid D, Guilband G: Are mechanical and cold allodynia in mononeuropathic and arthritic rats relieved by systemic treatment with calcitonin or guanethidine? Pain 1993, 52:41–47.

    Article  PubMed  CAS  Google Scholar 

  6. Shir Y, Seltzer Z: A-fibers mediate mechanical hyperesthesia and allodynia and C-fibers mediate thermal hyperalgesia in a new model of causalgia from pain disorders in rats. Neurosci Lett 1990, 115:62–67.

    Article  PubMed  CAS  Google Scholar 

  7. Ahlgren SC, Levine JD: Mechanical hyperalgesia in streptozotocin-diabetic rats is not sympathetically maintained. Brain Res 1993, 616:171–175.

    Article  PubMed  CAS  Google Scholar 

  8. Malmberg AB, Yaksh TL, Calcutt NA: Anti-nociceptive effects of the GM1 ganglioside derivative AGF44 on the formalin test in normal and streptozotocin-diabetic rats. Neurosci Lett 1993, 161:45–48.

    Article  PubMed  CAS  Google Scholar 

  9. Hao JX, Xu XJ, Aldskogius H, et al.: Photochemically induced transient spinal ischemia induces behavioral hypersensitivity to mechanical and cold stimuli, but not to noxious-heat stimuli, in the rat. Exp Neurol 1992, 118:187–194.

    Article  PubMed  CAS  Google Scholar 

  10. Marsala M, Yaksh T: Transient spinal ischemia in the rat: characterization of behavioral and histopathological consequences as a function of the duration of aortic occlusion. J Cereb Blood Flow Metab 1994, 14:526–5735.

    PubMed  CAS  Google Scholar 

  11. Sherman SE, Loomis CW: Morhpine insensitive allodynia is produced by intrathecal strychnine in the lightly anesthetized rat. Pain 1994, 56:17–29.

    Article  PubMed  CAS  Google Scholar 

  12. Yaksh TL: Behavioral and autonomic correlates of the tactile evoked allodynia produced by spinal glycine inhibition: effects of modulatory receptor systems and excitatory amino acid antagonists. Pain 1989, 37:111–123.

    Article  PubMed  CAS  Google Scholar 

  13. Chaplan SR, Calcutt NA, Yaksh TL: Pharmacology of tactile allodynia in the streptozotocin diabetic rat. Soc Neurosci Abstr 1995, 21:1172.

    Google Scholar 

  14. Yamamoto T, Yaksh TL: Spinal pharmacology of thermal hyperesthesia induced by incomplete ligation of sciatic nerve. I. Opioid and nonopioid receptors. Anesthesiology 1991, 75:817–826.

    Article  PubMed  CAS  Google Scholar 

  15. Lee Y-W, Chaplan SR, Yaksh TL: Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. Neurosci Lett 1995, 199:111–114.

    Article  PubMed  CAS  Google Scholar 

  16. Xu XJ, Hao JX, Seiger A, et al.: Systemic mexiletine relieves chronic allodynialike symptoms in rats with ischemic spinal cord injury. Anesth Analg 1992, 74:649–652.

    Article  PubMed  CAS  Google Scholar 

  17. Yaksh TL, Pogrel JW, Lee YW, Chaplan SR: Reversal of nerve ligation-induced allodynia by spinal alpha-2 adrenoreceptor agonists. J Pharmacol Exp Ther 1995, 272:207–214.

    PubMed  CAS  Google Scholar 

  18. Gracely RH, Lynch SA, Bennet GJ: Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain 1992, 51:175–194.

    Article  PubMed  CAS  Google Scholar 

  19. Grabow TS, Hurley RW, Banfor PN, et al.: Supraspinal and spinal delta(2) opioid receptor-mediated antinociceptive synergy is mediated by spinal alpha(2) adrenoceptors. Pain 1999, 83:47–55.

    Article  PubMed  CAS  Google Scholar 

  20. Budai D, Harasawa I, Fields HL: Midbrain periaqueductal gray (PAG) inhibits nociceptive inputs to sacral dorsal horn nociceptive neurons through alpha2-adrenergic receptors. J Neurophysiol 1998, 80:2244–2254.

    PubMed  CAS  Google Scholar 

  21. Arner S, Meyerson BA: Lack of analgesic effect of opioids on neuropathic and idiopathic form of pain. Pain 1988, 33:11–23.

    Article  PubMed  CAS  Google Scholar 

  22. Max MB, Byas-Smith MG, Gracely RH, Bennett GJ: Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Clin Neuropharmacol 1995, 18:360–368.

    Article  PubMed  CAS  Google Scholar 

  23. Leung A, Wallace MS, Ridgeway B, Yaksh TL: Concentrationeffect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain 2000, in press.

  24. Urban BJ, France RD, Steinberger DL, et al.: Long-term use of narcotic/antidepressant medication in the management of phantom limb pain. Pain 1983, 24:191–197.

    Article  Google Scholar 

  25. Zenz M, Strumpf M, Tryba M: Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage 1992, 7:69–77.

    Article  PubMed  CAS  Google Scholar 

  26. Do Quang-Cantagrel N, Wallace MS, Magnuson S: Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg 2000, 90:933–937.

    Article  PubMed  CAS  Google Scholar 

  27. Dellemijn PL, Vanneste JA: Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997, 349:753–758.

    Article  PubMed  CAS  Google Scholar 

  28. Watson CP, Babul N: Efficacy of oxycodone im neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998, 50:1837–1841.

    PubMed  CAS  Google Scholar 

  29. Hanks GW, Forbes K: Opioid responsiveness. Acta Anaesthesiol Scand 1997, 41(1 Pt 2):154–158.

    PubMed  CAS  Google Scholar 

  30. Rauck RL, Eisenach JC, Jackson K, et al.: Epidural clonidine treatment for refractory reflex sympathetic dystrophy. Anesthesiology 1993, 79:1163–1169.

    Article  PubMed  CAS  Google Scholar 

  31. Byas-Smith MG, Max MB, Muir J, Kingman A: Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage "enriched enrollment" design. Pain 1995, 60:267–274.

    Article  PubMed  CAS  Google Scholar 

  32. Buerkle H, Schäpsmeier M, Bantel C, et al.: Thermal and mechanical antinociceptive action of spinal versus peripherally administered clonidine in the rat inflamed knee joint model. Br J Anaesth 1999, 83:436–441.

    PubMed  CAS  Google Scholar 

  33. Gentili M, Juhel A, Bonnet F: Peripheral analgesic effect of intra-articular clonidine. Pain 1996, 64:593–596.

    Article  PubMed  CAS  Google Scholar 

  34. Hao JX, Yu W, Xu XJ, Wiesenfeld-Hallin Z: Effects of intrathecal vs. systemic clonidine in treating chronic allodynia-like response in spinally injured rats. Brain Res 1996, 736:28–34.

    Article  PubMed  CAS  Google Scholar 

  35. Epstein JB, Grushka M, Le N: Topical clonidine for orofacial pain: a pilot study. J Orofac Pain 1997, 11:346–352.

    PubMed  CAS  Google Scholar 

  36. Davis KD, Treede RD, Raja SN, et al.: Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain 1991, 47:309–317.

    Article  PubMed  CAS  Google Scholar 

  37. Taniguchi K, Yoshitake S, Iwasaka H: The effects of imipramine, amitriptyline and clonidine administered by iontophoresis on the pain threshold. Acta Anaesthesiol Belg 1995, 46:121–125.

    PubMed  CAS  Google Scholar 

  38. Coombs DW, Saunders RL, Fratkin JD, et al.: Continuous intrathecal hydromorphone and clonidine for intractable cancer pain. J Neurosurg 1986, 64:890–894.

    Article  PubMed  CAS  Google Scholar 

  39. Eisenach JC, Rauck RL, Buzzanell C, Lysak SZ: Epidural clonidine analgesia for intractable cancer pain: phase I. Anesthesiology 1989, 71:647–652.

    Article  PubMed  CAS  Google Scholar 

  40. Siddall PJ, Gray M, Rutkowski S, Cousins MJ: Intrathecal morphine and clonidine in the management of spinal cord injury pain: a case report. Pain 1994, 59:147–148.

    Article  PubMed  CAS  Google Scholar 

  41. Borg PAJ, Krijnen HJ: Long-term intrathecal administrtion of midazolam and clonidine. Clin J Pain 1996, 12:63–68.

    Article  PubMed  CAS  Google Scholar 

  42. Middleton JW, Siddall PJ, Walker S, et al.: Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study. Arch Phys Med Rehabil 1996, 77:824–826.

    Article  PubMed  CAS  Google Scholar 

  43. Eisenach JC, DuPen S, Dubois M, et al.: Epidural cloindine analgesia for intractable cancer pain. Pain 1995, 61:391–399.

    Article  PubMed  CAS  Google Scholar 

  44. Ozawa S, Kamiya H, Tsuzuki K: Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 1998, 54:581–618.

    Article  PubMed  CAS  Google Scholar 

  45. Mao J, Price DD, Hayes RL: Differential roles of NMDA and non-NMDA receptor activation in induction and maintenance of thermal hyperalgesia in rats with painful mononeuropathy. Brain Res 1992, 598:271–278.

    Article  PubMed  CAS  Google Scholar 

  46. Chaplan SR, Malmberg AB, Yaksh TL: Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exper Therap 1997, 280:828–838.

    Google Scholar 

  47. Xu XJ, Hao JX, Seiger A, Wiesenfeld-Hallin Z: Systemic excitatory amino acid receptor antagonists of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and the N-methyl-D-aspartate (NMDA) receptor relieve mechanical hypersensitivity after transient spinal cord ischemia in rats. J Pharmacol Exp Ther 1993, 267:140–144.

    PubMed  CAS  Google Scholar 

  48. Eide PK, Jorum E, Stubhaug A: Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind cross-over comparison with morphine, and placebo. Pain 1994, 58:347–354.

    Article  PubMed  CAS  Google Scholar 

  49. Pud D, Eisenberg, Spitzer A, et al.: The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain 1998, 75:349–354.

    Article  PubMed  CAS  Google Scholar 

  50. Nelson KA, Park KM, Robinovitz E, et al.: High-dose oral dextromethrophan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997, 48:1212–1218.

    PubMed  CAS  Google Scholar 

  51. Enarson MC, Hays H, Woodroffe MA: Clinical experience with oral ketamine. J Pain Symptom Manage 1999, 17:384–386.

    Article  PubMed  CAS  Google Scholar 

  52. Haines DR, Gaines SP: N of 1 randomised controlled trials of oral ketamine in patients with chronic pain. Pain 1999, 83:283–287.

    Article  PubMed  CAS  Google Scholar 

  53. Mercadante S, Lodi F, Sapio M, et al.: Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage 1995, 10:564–568.

    Article  PubMed  CAS  Google Scholar 

  54. Malmberg AB, Yaksh TL: Cyclo-oxygenase inhibition and the spinal release of prostaglandin E2 and amino acids evoked by paw formalin injection: a microkialysis study in unanesthetized rats. J Neurosci 1995, 15:2768–2776.

    PubMed  CAS  Google Scholar 

  55. Uda R, Horiguchi S, Ito S, Hyodo M: Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2 or F2a to conscious mice. Brain Res 1990, 510:26–32.

    Article  PubMed  CAS  Google Scholar 

  56. Minami T, Nishihara I, Uda R, et al.: Characterization of EP-receptor subtypes involved in allodynia and hyperalgesia induced by intrathecal administration of prostaglandin E2 to mice. Br J Pharmacol 1994, 112:735–740.

    PubMed  CAS  Google Scholar 

  57. Malmberg AB, Yaksh TL: Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclo-oxygenase inhibition. Science 1992, 257:1276–1279.

    Article  PubMed  CAS  Google Scholar 

  58. Syriatowicz JP, Hu D, Walker JS, et al.: Hyperalgesia due to nerve injury: role of prostaglandins. Neuroscience 1999, 94:587–594.

    Article  PubMed  CAS  Google Scholar 

  59. Ripamonti C, Ticozzi C, Zecca E, et al.: Continuous subcutaneous infusion of ketorolac in cancer neuropathic pain unresponsive to opioid and adjuvant drugs. A case report. Tumori 1996, 82:413–415.

    PubMed  CAS  Google Scholar 

  60. Akopian AN, Sivilotti L, Wood JN: A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature 1996, 379:257–262.

    Article  PubMed  CAS  Google Scholar 

  61. Jett MF, McGuirk J, Waligora D, Hunter JC: The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. Pain 1997, 69:161–169.

    Article  PubMed  CAS  Google Scholar 

  62. Kamei J, Hitosugi H, Kawashima N, et al.: Antinociceptive effect of mexiletine in diabetic mice. Res Comm Chem Pathol Pharmacol 1992, 77:245–248.

    CAS  Google Scholar 

  63. Devor M, Wall PD, Catalan N: Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 1992, 48:261–268.

    Article  PubMed  CAS  Google Scholar 

  64. Bach FW, Jensen TS, Kastrup J, et al.: The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy. Pain 1990, 40:29–34.

    Article  PubMed  CAS  Google Scholar 

  65. Rowbotham MC, Reisner-Keller LA, Fields HL: Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991, 41:1024–1028.

    PubMed  CAS  Google Scholar 

  66. Tanelian DL, Brose WG: Neuropathic pain can be relieved by drugs that are use-dependent sodium channel blockers: lidocaine, carbamazepine, and mexiletine. Anesthesiology 1991, 74:949–951.

    Article  PubMed  CAS  Google Scholar 

  67. Wallace MS, Ridgeway B, Leung A, Yaksh T: Concentrationeffect relationship of intravenous lidocaine on the allodynia of complex regional pain syndrome types I and II. Anesthesiology 2000, 92:75–83.

    Article  PubMed  CAS  Google Scholar 

  68. Galer BS, Harle J, Rowbotham MC: Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. J Pain Symptom Manage 1996, 12:161–167.

    Article  PubMed  CAS  Google Scholar 

  69. Stracke H, Meyer UE, Schumacher HE, Federlin K: Mexiletine in the treatment of diabetic neuropathy. Diabetes Care 1992, 15:1550–1555.

    Article  PubMed  CAS  Google Scholar 

  70. Nishiyama K, Sakuta M: Mexiletine for painful alcoholic neuropathy. Intern Med 1995, 34:577–579.

    PubMed  CAS  Google Scholar 

  71. Chabal C, Jacobson L, Mariano A, et al.: The use of oral mexiletine for the treatment of pain after peripheral nerve injury. Anesthesiology 1992, 76:513–517.

    Article  PubMed  CAS  Google Scholar 

  72. Awerbuch GI, Sandyk R: Mexiletine for thalamic pain syndrome. Int J Neurosci 1990, 55:129–133.

    PubMed  CAS  Google Scholar 

  73. Wright JM, Oki JC, Graves L: Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother 1997, 31:29–34.

    PubMed  CAS  Google Scholar 

  74. Chiou-Tan FY, Tuel SM, Johnson JC, et al.: Effect of mexiletine on spinal cord injury dysesthetic pain. Amer J Phys Med Rehabil 1996, 75:84–87.

    Article  CAS  Google Scholar 

  75. Wallace M, Magnuson S, Ridgeway B: Oral mexiletine in the treatment of neuropathic pain. Reg Anesth Pain Med 2000, 25:459–467.

    Article  PubMed  CAS  Google Scholar 

  76. Hunter JC, Gogas KR, Hedley LR, et al.: The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol 1997, 324:153–160.

    Article  PubMed  CAS  Google Scholar 

  77. Nakamura-Craig M, Follenfant RL: Effect of lamotrigine in the acute and chronic hyperalgesia induced by PGE2 and in the chronic hyperalgesia in rats with streptozotocin-induced diabetes. Pain 1995, 63:33–37.

    Article  PubMed  CAS  Google Scholar 

  78. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, et al.: Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain 1997, 73:223–230.

    Article  PubMed  CAS  Google Scholar 

  79. di Vadi PP, Hamann W: The use of lamotrigine in neuropathic pain. Anaesthesia 1998, 53:808–809.

    Article  PubMed  Google Scholar 

  80. Canavero S, Bonicalzi V: Lamotrigine control of central pain. Pain 1996, 68:179–181.

    Article  PubMed  CAS  Google Scholar 

  81. McCleane G: 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial. Pain 1999, 83:105–107. Using a double-blind, placebo-controlled control design, this paper showed no analgesic effect of lamotrigine (200 mg/d) in neuropathic pain. However, later preliminary studies have shown that the analgesic dose may be 400 mg/d, suggesting more studies are needed.

    Article  PubMed  CAS  Google Scholar 

  82. Chaplan SR, Pogrel JW, Yaksh TL: Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther 1994, 269:1117–1123.

    PubMed  CAS  Google Scholar 

  83. Hess P: Calcium channels in vertebrate cells. Annu Rev Neurosci 1990, 13:337–356.

    Article  PubMed  CAS  Google Scholar 

  84. Dunlap K, Luebke JI, Turner TJ: Exocytotic Ca2+ channels in mammalian central neurons. Trends Neurosci 1995, 18:89–98.

    Article  PubMed  CAS  Google Scholar 

  85. Vanegas H, Schaible HC: Effects of antagonists to highthreshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia. Pain 2000, 85:9–18.

    Article  PubMed  CAS  Google Scholar 

  86. Gohil K, Bell JR, Ramachandran J, Miljanich GP: Neuroanatomical distribution of receptors for a novel voltagesensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC). Brain Res 1994, 653:258–266.

    Article  PubMed  CAS  Google Scholar 

  87. Augustine GJ, Charlton MP, Smith SJ: Calcium action in synaptic transmitter release. Annu Rev Neurosci 1987, 10:633–693.

    Article  PubMed  CAS  Google Scholar 

  88. Scher E, Clementi F: Omega-conotoxin-sensitive voltageoperated calcium channels in vertebrate cells. Neuroscience 1991, 42:42301–42307.

    Google Scholar 

  89. Calcutt NA, Chaplan SR: Spinal pharmacology of tactile allodynia in diabetic rats. Br J Pharmacol 1997, 122:1478–1482.

    Article  PubMed  CAS  Google Scholar 

  90. White DM, Cousins MJ: Effect of subcutaneous administration of calcium channel blockers on nerve injury-induced hyperalgesia. Brain Res 1998, 801:50–58.

    Article  PubMed  CAS  Google Scholar 

  91. Santill’an R, Hurlé MA, Armijo JA, et al.: Nimodipine-enhanced opiate analgesia in cancer patients requiring morphine dose escalation: a double-blind, placebocontrolled study. Pain 1998, 76:17–26. Using a double-blind, placebo-controlled design, this paper showed a dramatic reduction in opioid requirement in cancer patients administered nimodopine (a calcium channel antagonist). The study supports combination therapy in neuropathic pain.

    Article  CAS  Google Scholar 

  92. Muizelaar JP, Kleyer M, Hertogs IA, DeLange DC: Complex regional pain syndrome (reflex sympathetic dystrophy and causalgia): management with the calcium channel blocker nifedipine and/or the alpha-sympathetic blocker phenoxybenzamine in 59 patients. Clin Neurol Neurosurg 1997, 99:26–30.

    Article  PubMed  CAS  Google Scholar 

  93. Bowersox SS, Gadbois T, Singh T, et al.: Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J Pharmacol Exp Ther 1996, 279:1243–1249.

    PubMed  CAS  Google Scholar 

  94. Yamamoto T, Sakashita Y: Differential effects of intrathecally administered N- and P-type voltage-sensitive calcium channel blocers upon two models of expermental monneuropathy in the rat. Brain Res 1998, 794:329–332.

    Article  PubMed  CAS  Google Scholar 

  95. Xiao WH, Bennett GJ: Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats. J Pharmacol Exp Ther 1995, 274:666–672.

    PubMed  CAS  Google Scholar 

  96. Brose WG, Gutlove DP, Luther RR, et al.: Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clin J Pain 1997, 13:256–259.

    Article  PubMed  CAS  Google Scholar 

  97. Presley R, Charapata S, Perrar-Brechner T, et al. Chronic, opioid-resistant, neuropathic pain: marked analgesic efficacy of intrathecal ziconotide. Presented at the 1998 Annual American Pain Society, San Diego, CA, A894.

  98. McGuire D, Bowersox S, Fellmann JD, Luther RR: Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans. J Cardiovasc Pharmacol 1997, 30:400–403.

    Article  PubMed  CAS  Google Scholar 

  99. Atanassoff PG, Wallace MS, Wendel D, et al. Analgesic efficacy of epidural ziconotide in acute postoperative pain. Paper presented at the 1998 Annual American Pain Society, San Diego, CA.

  100. Wallace MS, Presley R, Fisher R, et al.: Intrathecal dose titration evolution of Ziconotide, a novel analgesic N-type calcium channel blocker. Presented at the 2000 Annual Meeting, American Pain Society, Atlanta, GA.

  101. Mellick GA, Mellick LB: Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Rehabil 1997, 78:98–105.

    Article  PubMed  CAS  Google Scholar 

  102. Pan HL, Eisenach JC, Chen SR: Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther 1999, 288:1026–1030.

    PubMed  CAS  Google Scholar 

  103. LaBuda CJ, Fuchs PN: Morphine and gabapentin decrease mechanical hyperalgesia and escape/avoidance behavior in a rat model of neuropathic pain. Neurosci Lett 2000, 290:137–140.

    Article  PubMed  CAS  Google Scholar 

  104. Field MJ, McCleary S, Hughes J, Singh L: Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 1999, 80:391–398.

    Article  PubMed  CAS  Google Scholar 

  105. Hao JX, Xu XJ, Urban L, Wiesenfeld-Hallin Z: Repeated administration of systemic gabapentin alleviates allodynia-like behaviors in spinally injured rats. Neurosci Lett 2000, 280:211–214.

    Article  PubMed  CAS  Google Scholar 

  106. Suman-Chauhan N, Webdale L, Hill DR, Woodruff GN: Characterization of gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur J Pharmacol 1993, 244:293–301.

    Article  PubMed  CAS  Google Scholar 

  107. Gotz E, Feuerstein TJ, Lais A, Meyer DK: Effects of gabapentin on release of gamma-aminobutyric acid from slices of rat neostriatum. Arzneimittelforschung 1993, 43:636–638.

    PubMed  CAS  Google Scholar 

  108. Felix R: Voltage-dependent calcium channel alpha2delta auxillary subunit: structure, function and regulation. Receptors Channels 1999, 6:351–362.

    PubMed  CAS  Google Scholar 

  109. RowbothamM, Harden N, Stacey B, et al.: Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998, 280:1837–1863. Using a double-blind, placebo-controlled multicenter study, this paper showed a significant reduction in the pain of postherpetic neuralgia in patients administered gabapentin. This was the first controlled study to demonstrate efficacy of gabapentin in neuropathic pain and described therapeutic doses.

    Article  PubMed  CAS  Google Scholar 

  110. Backonja M, Beydoun A, Edwards KR, et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 1998, 280:1831–1836.

    Article  PubMed  CAS  Google Scholar 

  111. Esser MJ, Sawynok J: Acute amitriptyline in a rat model of neuropathic pain: differential symptom and route effects. Pain 1999, 80:643–653.

    Article  PubMed  CAS  Google Scholar 

  112. Lang E, Hord AH, Denson D: Venlafaxine hydrochloride (Effexor) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. Pain 1996, 68:151–155.

    Article  PubMed  CAS  Google Scholar 

  113. Max MB, Kishore-Kumar R, Schafer SC, et al.: Efficacy of desipramine in painful diabetic neuropathy: a placebo controlled trial. Pain 1991, 45:3–9.

    Article  PubMed  CAS  Google Scholar 

  114. Watson CPN, Chipman M, Reed K, et al.: Amitriptyline versus maprotiline in post-herpetic neuralgia: a randomized, double blind, crossover trial. Pain 1992, 48:29–36.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology, University of California, San Diego School of Medicine, 9500 Gilman Drive #0924, 92093, La Jolla, CA, USA

    Mark S. Wallace MD

Authors
  1. Mark S. Wallace MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wallace, M.S. Pharmacologic treatment of neuropathic pain. Current Science Inc 5, 138–150 (2001). https://doi.org/10.1007/s11916-001-0082-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-001-0082-2

Keywords

Search

Navigation